Delivering Integrated Safety and Efficacy Analyses in Cushing Syndrome

1 minute read

Published: October 6th, 2025

When faced with evolving analysis plans, minimal client infrastructure, and shifting output volumes, Phastar delivered high-quality ISS and ISE outputs for Cushing syndrome clinical studies. 

By combining automation, custom macros, and strategic agility within an FSP model, our team adapted quickly to changing sponsor needs—ensuring consistent quality and on-time delivery despite significant mid-project changes. 

This case study demonstrates how innovation, collaboration, and flexibility can transform complex integration challenges into regulatory-ready solutions that add lasting value for the sponsor. 

Complete the form to download the full case study.

Related articles

Transforming Uncertainty into Statistical Confidence: Simulation-Driven Design for a First-in-Human Reproductive Therapeutic 

Transforming Uncertainty into Statistical Confidence: Simulation-Driven Design for a First-in-Human Reproductive Therapeutic 

July 20th, 2026 1 minute read

Designing a first-in-human study is challenging. Designing one for a novel reproductive therapy with limited prior da...

Turning Complexity into Regulatory Confidence: Designing a Seamless Phase 2b/3 Strategy for FDA Engagement 

Turning Complexity into Regulatory Confidence: Designing a Seamless Phase 2b/3 Strategy for FDA Engagement 

July 20th, 2026 1 minute read

Accelerating clinical development requires more than speed, it demands a careful balance between innovation, scientif...

Enabling First-in-Human Trial Success: Delivering an Innovative Bayesian Phase I/II Oncology Design 

Enabling First-in-Human Trial Success: Delivering an Innovative Bayesian Phase I/II Oncology Design 

July 20th, 2026 1 minute read

Helping an Emerging Biotech Navigate Complex Clinical Development Preparing for a first-in-human clinical trial prese...